A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Nivolumab (Primary) ; Adjuvants
Indications Malignant melanoma
Focus Adverse reactions

16 Jan 2024 Status changed from recruiting to active, no longer recruiting.
10 Nov 2021 Planned End Date changed from 30 Sep 2026 to 30 Sep 2028.
10 Nov 2021 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com